RARE - Ultragenyx upped at Goldman Sachs on bone disorder treatment
2024-06-06 07:49:18 ET
More on Ultragenyx Pharmaceutical
- Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet
- Ultragenyx Phase 3 study for DTX401 meets primary endpoint
- Ultragenyx Pharmaceutical GAAP EPS of -$2.03 misses by $0.28, revenue of $108.8M misses by $7.64M
- Ultragenyx Pharmaceutical, Inc. (RARE) Q1 2024 Earnings Call Transcript
- Seeking Alpha's Quant Rating on Ultragenyx Pharmaceutical